Safety, pharmacodynamics, and potential benefit of omaveloxolone in Friedreich ataxia
Annals of Clinical and Translational Neurology2018Vol. 6(1), pp. 15–26
Citations Over TimeTop 10% of 2018 papers
David R. Lynch, Jennifer Farmer, Lauren Hauser, Ian A. Blair, Qing Qing Wang, Clementina Mesaros, Nathaniel W. Snyder, Sylvia Boesch, Melanie Chin, Martin B. Delatycki, Paola Giunti, Angela Goldsberry, Chad Hoyle, Michael G. McBride, Wolfgang Nachbauer, Megan O’Grady, Susan Perlman, S. H. Subramony, George Wilmot, Theresa A. Zesiewicz, Colin J. Meyer
Abstract
Treatment of Friedreich ataxia patients with omaveloxolone at the optimal dose level of 160 mg/day appears to improve neurological function. Therefore, omaveloxolone treatment is being examined in greater detail at 150 mg/day for Friedreich ataxia.
Related Papers
- → Idebenone and reduced cardiac hypertrophy in Friedreich's ataxia(2002)246 cited
- → Idebenone delays the onset of cardiac functional alteration without correction of Fe-S enzymes deficit in a mouse model for Friedreich ataxia(2004)134 cited
- → The use of antioxidants in Friedreich’s ataxia treatment(2003)25 cited
- → Evaluation of the Cases with Friedreich Ataxia(2013)2 cited
- [Successful idebenone therapy of hypertrophic cardiomyopathy in Friedreich ataxia].(2003)